Dr. Reddy's Laboratories

• Should These Drug Companies Continue to Pay a Dividend?

  By Chris Hodge - May 24, 2013 | Tickers: AGN, RDY, NVO

  Editor's Note: The article has been modified to better describe the current companies' dividend arrangements.

  Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusions about their dividend arrangements. In short, should these companies continue to pay dividends more »

• Five Stocks Recently Sold By Manning and Napier

  By Dr. Osman Gulseven - December 11, 2012 | Tickers: CL, RDY, FDX, UL, DIS

  Established in 1970 by Bill Manning and Bill Napier, Manning & Napier is on of the largest fund management companies in the U.S. For more than four decades, Manning & Napier has been leading institutional and individual clients towards their financial goals. Manning and Napier have an opportunistic investment style. The management aims to assist investors to meet a broad range of investment requirements even in the most challenging environments. As more »

• An Interesting Emerging Market ADR

  By Shas Dey - November 21, 2012 | Tickers: RDY, GSK, PFE, TEVA

  Dr. Reddy’s Laboratories (NYSE: RDY) is an India-based integrated global pharmaceutical company. RDY is one of the largest pharmaceutical companies in India, with revenue of $2 billion in FY 2012. The company focuses on three core businesses; Pharmaceutical Services and Active Ingredients, Global Generics, and Proprietary Products.

  Pharmaceutical Services & Active Ingredients (PSAI)

  Through the PSAI unit, RDY offers speedy product development with IP advantages, as well as cost effective more »